Five hundred forty-two specimens of 150 children enrolled in the AML-Berlin-Frankfurt-Muenster (BFM) 98 study were analyzed by four-color immunophenotyping at up to four predefined time points during ...
The most-read coverage of the latest updates in acute myeloid leukemia (AML) for 2025 focused on the evolution of targeted therapies, the promise of off-the-shelf chimeric antigen receptor (CAR) ...
In the HARMONY Alliance Study of European randomized clinical trials, researchers sought to determine if MRD could serve as an intermediate endpoint in intensively treated AML.
Correction to "Clinical application of flow cytometry in patients with unexplained cytopenia and suspected myelodysplastic syndrome: A report of the European LeukemiaNet International MDS-Flow ...
Two unique case reports highlight the diagnostic challenges and critical importance of comprehensive immunophenotyping in cases of T-cell acute lymphoblastic leukemia/lymphoma that present without ...
John Routzahn, University of Delaware class of 2024 Applied Molecular Biology and Biotechnology (AMBB), won an NIH grant to do summer research at the National Cancer Institute in Fort Detrick as part ...
“Corticosteroids are well established as a highly effective component of treatment to induce remission in ALL; thus, processes that increase endogenous corticosteroid production may be responsible for ...
Mixed phenotype acute leukemia has qualities of both lymphoid and myeloid leukemias. These mixed qualities make it very difficult to diagnose and treat. The outlook for people with this type of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback